



USCDI Task Force 2021 Kickoff

Steven Lane, Co-Chair

Terry O'Malley, Co-Chair

February 2, 2021

Meeting Agenda

- Call to Order/Roll Call
- Welcome and Introductions
- Overview of Task Force Charge
- Summary of Draft USCDI v2
- Task/Charge Priorities and Breakdown
- Timeline and Meeting Schedule
- Public Comment
- Adjourn

Task Force Roster

Name	Organization
Steven Lane (Co-Chair)	Sutter Health
Terry O'Malley (Co-Chair)	Individual
Ricky Bloomfield	Apple
Hans Buitendijk	Cerner
Valerie Grey	New York eHealth Collaborative
Jim Jirjis	HCA Healthcare
Ken Kawamoto	University of Utah Health
Leslie Kelly Hall	Engaging Patient Strategy
Leslie Lenert	Medical University of South Carolina
Clement McDonald	National Library of Medicine

Name	Organization
Aaron Miri	University of Texas at Austin
Brett Oliver	Baptist Health
Mark Savage	University of California, San Francisco
Michelle Schreiber	CMS
Sasha TerMaat	Epic
Andrew Truscott	Accenture
Sheryl Turney	Anthem, Inc.
Dan Vreeman	RTI International
Denise Webb	Indiana Hemophilia and Thrombosis Center

Task Force Charge

Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

Specific charges:

- | | <u>Due</u> |
|--|--------------------------|
| <ul style="list-style-type: none"> • Evaluate Draft USCDI v2 and provide HITAC with recommendations for: <ul style="list-style-type: none"> • Data classes and elements from USCDI v1 including applicable standards version updates • New data classes and elements from Draft USCDI v2 including applicable standards • Level 2 data classes and elements not included in Draft USCDI v2 | April 15, 2021 |
| <ul style="list-style-type: none"> • Evaluate the USCDI expansion process and provide HITAC with recommendations for: <ul style="list-style-type: none"> • ONDEC submission system improvements • Evaluation criteria and process used to assign levels to submitted data classes and elements • Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2 | September 9, 2021 |
| <ul style="list-style-type: none"> • Recommend prioritization areas for USCDI version 3 submission cycle | September 9, 2021 |



USCDI ONDEC Submissions – Version 2

Level Assignments	Data Elements
Level 2	109
Level 1	55
Comment Level	140
Total Data Elements Submitted	664*

***Includes Merged/Duplicated data elements**



Submission Evaluation Criteria

CRITERIA	COMMENT LEVEL	LEVEL 1	LEVEL 2
Maturity-Current Standards	May be represented by terminology standard <u>or</u> element of Standards Development Organization (SDO) balloted technical specification	<u>Must</u> be represented using terminology standard <u>or</u> element of SDO-balloted technical specification	<u>Must</u> be represented using terminology standard <u>or</u> element of SDO-balloted technical specification
Maturity-Current Use	Limited test environments, or pilots	Limited production environments, 1 or 2 different systems	At scale in production environments more than 2 different systems
Maturity-Current Exchange	Limited exchange with external organizations, on same or different EHR/HIT systems	Exchanged between 2 or 3 organizations with different EHR/HIT systems	Exchanged between 4 or more organizations with different EHR/HIT systems
Use Cases-# Stakeholders Impacted	Used by few stakeholders, or for narrowly defined conditions or events.	Pertinent to many, but not most patients, providers or events requiring its use	Pertains to majority of patients, providers or events requiring its use

Draft USCDI version 2 Update Process

ONC Prioritization criteria for Level 2 data elements

- Significant gaps in USCDI v1 concepts
- Supported by existing ONC Certification
- Modest technical standards development
- Modest aggregate lift for vendor development and implementation, esp. during pandemic

Allergies and Intolerances <ul style="list-style-type: none"> • Substance (Medication) • Substance (Drug Class) • Reaction 	Diagnostic Imaging <ul style="list-style-type: none"> • Diagnostic Imaging Order • Diagnostic Imaging Report • Diagnostic Imaging Narrative 	Laboratory <ul style="list-style-type: none"> • Tests • Values/Results • Laboratory Report Narrative • Pathology Report Narrative 	Problems <ul style="list-style-type: none"> • Problems • Date of Diagnosis • Date of Resolution 	Vital Signs <ul style="list-style-type: none"> • Diastolic Blood Pressure • Systolic Blood Pressure • Body Height • Body Weight • Heart Rate • Respiratory Rate • Body Temperature • Pulse Oximetry • Inhaled Oxygen Concentration • BMI Percentile (2-20 Years) • Weight-for-length Percentile (Birth-36 Months) • Occipital-frontal Head Circumference Percentile (Birth-36 Months)
Assessment and Plan of Treatment <ul style="list-style-type: none"> • Assessment and Plan of Treatment 	Encounter Information <ul style="list-style-type: none"> • Encounter Type • Encounter Diagnosis • Encounter Time 	Medications <ul style="list-style-type: none"> • Medications 	Procedures <ul style="list-style-type: none"> • Procedures 	
Care Team Members <ul style="list-style-type: none"> • Care Team Members • Provider Name • Provider Identifier 	Goals <ul style="list-style-type: none"> • Patient Goals 	Patient Demographics <ul style="list-style-type: none"> • First Name • Last Name • Previous Name • Middle Name (incl. middle initial) • Suffix • Birth Sex • Date of Birth • Race • Ethnicity • Preferred Language • Current Address • Previous Address • Phone Number • Phone Number Type • Email Address 	Provenance <ul style="list-style-type: none"> • Author Time Stamp • Author Organization 	
Clinical Notes <ul style="list-style-type: none"> • Consultation Note • Discharge Summary Note • History & Physical • Procedure Note • Progress Note 	Health Concerns <ul style="list-style-type: none"> • Health Concerns 		Smoking Status <ul style="list-style-type: none"> • Smoking Status 	
Clinical Notes <ul style="list-style-type: none"> • Consultation Note • Discharge Summary Note • History & Physical • Procedure Note • Progress Note 	Immunizations <ul style="list-style-type: none"> • Immunizations 		Unique Device Identifier(s) for a Patient's Implantable Device(s) <ul style="list-style-type: none"> • Unique Device Identifier(s) for a Patient's Implantable Device(s) 	


Key  New Data Class or Element
 Data Element reclassified

USCDI Version Update Process

2020

2021

2022



Task/Charge Priorities and Breakdown

Overarching charge:

Review and feedback on the Draft USCDI Version 2 content and process

Specific charges:

- | | <u>Due</u> |
|--|--------------------------|
| <ul style="list-style-type: none"> • Evaluate Draft USCDI v2 and provide HITAC with recommendations for: <ul style="list-style-type: none"> • Data classes and elements from USCDI v1 including applicable standards version updates • New data classes and elements from Draft USCDI v2 including applicable standards • Level 2 data classes and elements not included in Draft USCDI v2 | April 15, 2021 |
| <ul style="list-style-type: none"> • Evaluate the USCDI expansion process and provide HITAC with recommendations for: <ul style="list-style-type: none"> • ONDEC submission system improvements • Evaluation criteria and process used to assign levels to submitted data classes and elements • Prioritization process used by ONC to select new data classes and elements for Draft USCDI v2 | September 9, 2021 |
| <ul style="list-style-type: none"> • Recommend prioritization areas for USCDI version 3 submission cycle | September 9, 2021 |

Next TF Meetings

- February 9, 2021, 10:30 am - 12:00 pm ET
- February 16, 2021, 10:30 am - 12:00 pm ET
- February 23, 2021, 10:30 am - 12:00 pm ET

Public Comment

To make a comment please call:
Dial: 1-877-407-7192

*(Once connected, press “*1” to speak)*

All public comments will be limited to three minutes.

You may enter a comment in the
“Public Comment” field below this presentation.

Or, email your public comment to onc-hitac@accelsolutionsllc.com.

*Written comments will not be read at this time,
but they will be delivered to members of the Task Force and made part of the Public Record.*

A large, abstract graphic on the left side of the slide, composed of numerous overlapping triangles and polygons in various shades of blue, green, yellow, and orange, creating a complex, multi-dimensional geometric pattern.

Questions?



Meeting Adjourned